Dicyclomine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Dicyclomine: From Irritable Bowel Syndrome to Cauda Equina Syndrome
One-Sentence Summary
Dicyclomine is an antimuscarinic antispasmodic, originally used for irritable bowel syndrome, and also linked to Clostridium difficile colitis and neurocirculatory asthenia in the knowledge graph. The TxGNN model predicts it may be effective for cauda equina syndrome, but there are currently 0 clinical trials and 0 publications supporting this direction. The prediction is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Irritable bowel syndrome (from the knowledge graph; no approved indication text is available for the Singapore licences) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 99.66% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 4 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, dicyclomine is an antimuscarinic antispasmodic that relaxes smooth muscle in the gut. Its efficacy in functional bowel disorders is established, and mechanistically it may be applicable to smooth-muscle spasm in other organs.
In cauda equina syndrome, the bowel and bladder dysfunction could in theory be eased by reduced detrusor overactivity and smooth muscle spasm. This is a symptom-level rationale only. Dicyclomine does not address the underlying nerve root compression, which needs surgical decompression. The very high TxGNN score is a computational prediction with no clinical trial or literature support.
Other predictions in the list are more biologically coherent but equally unsupported by studies:
- Obsolete neurogenic bladder (score 99.50%): Antimuscarinic blockade of detrusor receptors is a well-established mechanism. Agents such as oxybutynin already cover this space, and the disease term is obsolete and should be mapped to a current ontology entry.
- Gastroduodenitis (95.61%) and peptic ulcer disease (93.26%): Antispasmodic and antisecretory effects could give symptomatic relief only. Proton pump inhibitors, H2 blockers and H. pylori eradication are the standard of care.
- Autonomic nervous system disease (87.96%): Indirectly plausible, since neurocirculatory asthenia is an autonomic-type disorder, but the term is broad and anticholinergic side effects could worsen some conditions.
- ADHD, specific developmental disorder, chondromyxoid fibroma and faciodigitogenital syndrome: No credible mechanistic link was identified, and these predictions are probably network artifacts.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN10344P | ACOLIC SYRUP | Syrup | Not stated |
| SIN03333P | COLIMIX SYRUP | Syrup | Not stated |
| SIN10845P | MECLOSIL TABLET | Tablet | Not stated |
| SIN02547P | VERAGEL-DMS TABLET | Tablet | Not stated |
Safety Considerations
- Contraindications (from knowledge-graph disease associations, not label text): Conditions linked to dicyclomine include:
- Angle-closure glaucoma
- Benign prostatic hyperplasia
- Liver disease, liver failure, hepatic coma and hepatic encephalopathy
- Kidney disease
- Gastric ulcer
- Coronary artery disease
- Hypertension
- Porphyria
- Blood disorders (thrombocytopenia, neutropenia, agranulocytosis, anaemia)
- Sleep apnoea
- Anxiety and neurotic disorders
- Substance abuse or dependence
- Gallbladder disease
- Drug Interactions: 100 interactions were found. Most of those listed are Moderate, including:
- Opioids: fentanyl, alfentanil, codeine, dihydrocodeine, tramadol
- Other anticholinergic or antihistamine agents: chlorpheniramine, acrivastine, phenyltoloxamine, hyoscyamine, aclidinium, amitriptyline
- Others: ethanol, loperamide, amantadine, galantamine, acebutolol, botulinum toxin type A, acetylcholine
Minor interactions include acetaminophen and hydrochlorothiazide.
- Anticholinergic adverse effects (tachycardia, urinary retention, cognitive impairment) may be relevant to several predicted indications.
Please also refer to the package insert for the full warnings, as label text was not available for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication of cauda equina syndrome rests on a high TxGNN score alone, with no trials or publications. The rationale is symptom-level only and does not address the underlying cause. The drug is already marketed in Singapore, but only for its existing uses.
To proceed, the following is needed:
- Mechanism of action data
- Package insert warnings and contraindications from the Singapore regulator
- Approved indication text for the Singapore licences
- A literature and trial search specific to dicyclomine in neurogenic bowel and bladder dysfunction
- Mapping of the obsolete "neurogenic bladder" term to a current ontology entry
- A review of whether the more plausible candidates (neurogenic bladder, gastroduodenitis) are worth pursuing as symptomatic indications, given established alternatives
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.